Soluble forms of the immune check-point receptor PD-1 and its ligand PD-L1 in blood serum of patients with renal cell carcinoma: clinical and pathologic correlations-Reference-Cited by-同舟云学术

Soluble forms of the immune check-point receptor PD-1 and its ligand PD-L1 in blood serum of patients with renal cell carcinoma: clinical and pathologic correlations

Published:2019-04-09 Issue:1 Volume:15 Page:15-22
ISSN:1996-1812
Container-title:Cancer Urology
language:
Short-container-title:Onkourologiâ

Author:

Kushlinskii N. E.¹^ORCID,Gershtein E. S.¹^ORCID,Goryatcheva I. O.²^ORCID,Morozov A. A.³^ORCID,Alferov A. A.¹^ORCID,Bezhanova S. D.¹^ORCID,Kazantseva I. A.³^ORCID,Bazaev V. V.³^ORCID,Matveev V. B.¹^ORCID

Affiliation:

1. National Medical Research Center of Oncology, Ministry of Health of Russia

2. National Medical Research Center of Oncology, Ministry of Health of Russiaatcheva1

3. M.F. Vladimirsky Moscow Regional Research and Clinical Institute

Publisher

Publishing House ABV Press

Subject

Urology,Nephrology,Radiology Nuclear Medicine and imaging,Oncology,Surgery

Reference24 articles.

1. Ainsworth N.L., Lee J.S., Eisen T. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2009;9(12):1793—805.DOI: 10.1586/era.09.144.PMID: 19954291.

2. Bracarda S., Porta C., Boni C. et al. Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferonalpha 2a (RAPSODY). Eur Urol 2013;63(2):254—61. DOI: 10.1016/j.eururo.2012.08.027. PMID: 22964169.

3. Procopio G., Verzoni E., Bracarda S. et al. Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. Ann Oncol 2013;24(12):2967—71. DOI: 10.1093/annonc/mdt375. PMID: 24063860.

4. Kushlinskii N.E., Fridman M.V., Morozov A.A. et al. Modern approaches to kid¬ney cancer immunotherapy. Cancer Urology 2018;14(2):54—67. (In Russ.).

5. Hamanishi J., Mandai M., Matsumura N. et al. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol 2016;21(3):462—73. DOI: 10.1007/s10147-016-0959-z. PMID: 26899259.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EXPRESSION OF PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) AND ITS LIGAND PD-L1 IN HIGH-GRADE SEROUS OVARIAN CANCER;Ulyanovsk Medico-biological Journal;2023-09-29

2. sPD-1/sPD-L1 proteins in non-small cell lung cancer and esophageal squamous cell carcinoma;Bulletin of Siberian Medicine;2022-10-14

3. Prognostic significance of sPD-1/sPD-L1 in renal cancer depending on the phenotype of tumor and stromal cells;Cancer Urology;2022-08-11

4. Clinical and prognostic significance of the soluble form of the VISTA immunity control point in patients with primary bone tumors;Russian Clinical Laboratory Diagnostics;2021-09-10

5. Prognostic significance of soluble forms of immune checkpoint PD-1/PDL1 receptor and ligand in blood plasma of gastric cancer patients;Russian Clinical Laboratory Diagnostics;2021-03-30